H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy

H.C. Wainwright reiterated its Buy rating and $25 price target on Ocular Therapeutix, whose shares were at $6.29 after falling 13% over the past week and trading near their 52-week low of $6.00. The firm said EyePoint’s DURAVYU failure to show non-inferiority in the Phase 3 LUCIA trial should not be extrapolated to Ocular’s AXPAXLI because of differences in pharmacology, delivery and trial design. The article also cites four analysts recently revising earnings upward and Ocular’s plan to submit an Axpaxli NDA in Q4 2026 following a completed FDA Pre-NDA meeting.

Analysis

EyePoint’s miss is a sentiment read-through, not a clean read-through on Ocular Therapeutix: drug pharmacology, delivery and trial design differ, so the result does not establish that AXPAXLI will fail. But it raises the evidentiary bar for the long-acting retinal-therapy thesis. If physicians and investors become more cautious about replacing established anti-VEGF regimens, REGN and Roche could retain longer-than-expected franchise durability; that is a competitive benefit even if the programs are not clinically comparable.

For OCUL, the key near-term issue is execution, not the sell-side target. A planned Q4 2026 NDA submission is a filing catalyst, not proof of approval, commercial uptake or the analyst sales forecasts. The 6–18 month value path remains exposed to clinical/regulatory review, safety, durability and adoption; the article provides no cash-runway or pivotal-data detail to underwrite downside. At a 52-week-low area, the stock may already discount skepticism, but that alone does not establish cheapness. The contrarian opportunity is that one competitor’s failure could create an indiscriminate class-level de-rating; the counterpoint is that differentiation must be demonstrated in OCUL’s own data.

Key Decisions for Investors

• Do not buy OCUL solely on H.C. Wainwright’s reiterated target or the EYPT read-through. Treat the Q4 2026 NDA filing as a near-term verification catalyst; confirm filing status, FDA meeting details and the underlying efficacy/safety package before adding risk.
• For a bullish expression, consider only a small, defined-risk OCUL call spread rather than unhedged biotech exposure, and size it around the binary regulatory and clinical risk. No entry premium or payoff can be responsibly specified without current option pricing and event timing.
• Watch REGN and Roche as relative beneficiaries if long-acting entrants continue to disappoint: a durable shift back toward incumbent therapies would support the competitive thesis, while credible OCUL data and timely regulatory progress would weaken it.
• Falsifiers: OCUL delays the stated NDA timetable, FDA feedback requires additional evidence, or company-reported data undermine efficacy, durability or safety. A sustained break below the cited $6 52-week-low area would also signal that market skepticism is intensifying, not resolving.